Your browser doesn't support javascript.
loading
Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.
Amanna, Ian J; Thomas, Archana; Engelmann, Flora; Hammarlund, Erika; Raué, Hans-Peter; Bailey, Adam L; Poore, Elizabeth A; Quintel, Benjamin K; Lewis, Anne D; Axthelm, Michael K; Johnson, Amanda L; Colgin, Lois M A; Diamond, Michael S; Messaoudi, Ilhem; Slifka, Mark K.
Afiliação
  • Amanna IJ; Najít Technologies, Inc., Beaverton, OR 97006, USA.
  • Thomas A; Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
  • Engelmann F; Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky, College of Medicine, Lexington, KY 40506, USA.
  • Hammarlund E; Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
  • Raué HP; Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
  • Bailey AL; Department of Pathology & Laboratory Medicine, University of Wisconsin - Madison, Madison, WI 53706, USA.
  • Poore EA; Najít Technologies, Inc., Beaverton, OR 97006, USA.
  • Quintel BK; Najít Technologies, Inc., Beaverton, OR 97006, USA.
  • Lewis AD; Division of Comparative Medicine, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
  • Axthelm MK; Division of Pathobiology & Immunology, Oregon National Primate Research Center, and The Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR 97006, USA.
  • Johnson AL; Division of Comparative Medicine, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
  • Colgin LMA; Division of Comparative Medicine, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
  • Diamond MS; Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Messaoudi I; Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky, College of Medicine, Lexington, KY 40506, USA.
  • Slifka MK; Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA. Electronic address: slifkam@ohsu.edu.
Cell Rep Med ; 5(7): 101655, 2024 Jul 16.
Article em En | MEDLINE | ID: mdl-39019010
ABSTRACT
Yellow fever virus (YFV) is endemic in >40 countries and causes viscerotropic disease with up to 20%-60% mortality. Successful live-attenuated yellow fever (YF) vaccines were developed in the mid-1930s, but their use is restricted or formally contraindicated in vulnerable populations including infants, the elderly, and people with compromised immune systems. In these studies, we describe the development of a next-generation hydrogen peroxide-inactivated YF vaccine and determine immune correlates of protection based on log neutralizing index (LNI) and neutralizing titer-50% (NT50) studies. In addition, we compare neutralizing antibody responses and protective efficacy of hydrogen peroxide-inactivated YF vaccine candidates to live-attenuated YFV-17D (YF-VAX) in a rhesus macaque model of viscerotropic YF. Our results indicate that an optimized, inactivated YF vaccine elicits protective antibody responses that prevent viral dissemination and lethal infection in rhesus macaques and may be a suitable alternative for vaccinating vulnerable populations who are not eligible to receive replicating live-attenuated YF vaccines.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Febre Amarela / Vírus da Febre Amarela / Vacinas de Produtos Inativados / Vacina contra Febre Amarela / Modelos Animais de Doenças / Anticorpos Neutralizantes / Peróxido de Hidrogênio / Macaca mulatta / Anticorpos Antivirais Limite: Animals / Humans Idioma: En Revista: Cell Rep Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Febre Amarela / Vírus da Febre Amarela / Vacinas de Produtos Inativados / Vacina contra Febre Amarela / Modelos Animais de Doenças / Anticorpos Neutralizantes / Peróxido de Hidrogênio / Macaca mulatta / Anticorpos Antivirais Limite: Animals / Humans Idioma: En Revista: Cell Rep Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos